BPOM Strives to Make Indonesia a Global Clinical Trial Hub
The Head of the Indonesian Food and Drug Authority (BPOM), Taruna Ikrar, recently expressed a grand ambition to make Indonesia a global clinical trial hub. This step is being taken as an effort to improve the quality of the health and research sectors in the country so that they can compete at an international level.
In his statement, Taruna Ikrar emphasized the importance of building a sustainable research ecosystem. According to him, Indonesia has great potential to become a primary destination for global pharmaceutical companies to conduct testing for new drugs and vaccines before they are marketed widely.
The development of this ecosystem includes upgrading laboratory facilities, strengthening transparent regulations, and collaborating with local researchers. With standards that are recognized globally, Indonesia is expected to attract more investment in the fields of biotechnology and health.
In addition to providing economic benefits, this initiative also aims to accelerate the access of the Indonesian people to innovative and high-quality medical treatments. By becoming a clinical trial hub, Indonesia will be more directly involved in the development of future medical technology.
As a next step, BPOM will continue to coordinate with various relevant parties to ensure that the entire research process runs in accordance with international safety standards. The hope is that this vision can strengthen Indonesia's position on the global health map in the future.